Johnson & Johnson $JNJ Holdings Increased by Integrity Alliance LLC.

Integrity Alliance LLC. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 239.0% during the first quarter, Holdings Channel reports. The institutional investor owned 32,018 shares of the company’s stock after acquiring an additional 22,572 shares during the period. Integrity Alliance LLC.’s holdings in Johnson & Johnson were worth $5,310,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Brighton Jones LLC raised its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares in the last quarter. Hudson Value Partners LLC raised its position in shares of Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock worth $5,648,000 after buying an additional 1,022 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Johnson & Johnson by 3.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 323,830 shares of the company’s stock worth $46,827,000 after buying an additional 10,387 shares in the last quarter. Minot DeBlois Advisors LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $927,000. Finally, Measured Risk Portfolios Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $1,160,000. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Bank of America lifted their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Thursday, July 17th. Leerink Partnrs cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. UBS Group lifted their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 17th. Finally, Barclays lifted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $176.29.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $177.12 on Wednesday. The firm’s 50 day simple moving average is $169.51 and its 200-day simple moving average is $161.02. The company has a market cap of $426.57 billion, a P/E ratio of 18.94, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson’s payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.